Search clinical trials for: rituximab,fludarabine, cyclophosphamide

Total 6688 results

Pfizer
UCB Pharma

Terminated

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Follicular

Belgium, United States, Canada, Hong Kong, Korea, Republic of, Portugal, Spain, Poland, India, Argentina, Italy, Mexico, Russian Federation, South Africa
National Cancer Institute (NCI)

Completed

Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis

Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center

Terminated

Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies

Lymphoma | Leukemia | Myeloma

United States
Alentis Therapeutics AG

Recruiting

Rescue of Nephrons With ALE.F02 (RENAL-F02) (RENAL-F02)

Glomerulonephritis Rapidly Progressive

Czechia, Spain, Germany, Denmark, Italy, United Kingdom, France, Switzerland, Sweden, Turkey
M.D. Anderson Cancer Center

Recruiting

Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances

Hematological Malignancy

United States
UNC Lineberger Comprehensive Cancer Center

Not yet recruiting

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

Ovarian Cancer | Epithelial Ovarian Cancer | Ovary Neoplasm | Recurrent

United States
ImmunityBio, Inc.

Recruiting

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

Non Hodgkin's Lymphoma Refractory/Relapsed

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma

Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent Aggressive Non-Hodgkin Lymphoma | Recurrent Burkitt Lymphoma | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Completed

Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
Lymphoma Study Association

Completed

ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma

Diffuse Large Cell Lymphoma

France, Belgium, Switzerland
University of Wisconsin, Madison

Completed

TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma

Lymphoma

United States
The Affiliated Hospital of Xuzhou Medical University
Guangzhou Bioresette Biomedical Technology Co., Ltd.

Recruiting

BGT007 Cell Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Hospital Universitario 12 de Octubre
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz; Fundación... and other collaborators

Completed

Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy (STARMEN)

MEMBRANOUS NEPHROPATHY

Spain
RenJi Hospital

Not yet recruiting

Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial

Efficacy and Safety
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children

Malignant Brain Neoplasm | Recurrent Malignant Brain Neoplasm | Refractory Malignant Brain Neoplasm

United States
M.D. Anderson Cancer Center
Ziopharm Oncology

Terminated

CD19-Specific T Cells Post AlloSCT

Recurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory B Acute Lymphoblastic Leukemia | Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory... and other conditions

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer

Breast Cancer

United States
Baylor College of Medicine
Center for Cell and Gene Therapy, Baylor College of Medicine

Recruiting

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

Liposarcoma | Liver Cancer | Rhabdomyosarcoma | Wilms Tumor | Malignant Rhabdoid Tumor | Yolk Sac Tumor

United States
Inge Marie Svane
Technical University of Denmark

Recruiting

ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma

Malignant Melanoma

Denmark
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Columbia University; Emory University; Rutgers...

Completed

Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Lymphoma | Leukemia

United States
Shams Shakil
Celgene

Completed

Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma

Lymphoma | Lymphoma, Non-Hodgkin | Hodgkin Disease

United States
Emory University
Celgene Corporation

Terminated

A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)

Leukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Lymphoma, Small Lymphocytic

United States
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... and other collaborators

Recruiting

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT

Allogeneic Hematopoietic Stem Cell Transplantation | Conditioning | Secondary Acute Myeloid Leukemia Evolving From MDS

China
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... and other collaborators

Recruiting

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

Myelodysplastic Syndrome | Allogeneic Hematopoietic Stem Cell Transplantation | Conditioning

China
Beth Israel Deaconess Medical Center
Bayer

Completed

Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders

Multiple Myeloma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | AML | Myelodysplastic Syndrome | Aplastic Anemia | Myeloproliferative Disorder | CLL | ALL

United States
University College, London

Active, not recruiting

Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (UKALL14)

Leukemia | Mucositis | Oral Complications

United Kingdom
Jonsson Comprehensive Cancer Center
Parker Institute for Cancer Immunotherapy

Recruiting

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Recurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | CD20 Positive | Refractory Mantle Cell Lymphoma | Recurrent Chronic Lymphocytic Leukemia | Refractory... and other conditions

United States
Inge Marie Svane
Adaptimmune

Not yet recruiting

To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma (ADP-TILIL7)

Melanoma | Melanoma Stage IV | Melanoma Stage III
National Institute of Arthritis and Musculoskeletal...

Completed

A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis

Psoriasis | Arthritis, Psoriatic

United States
The Affiliated Hospital of Xuzhou Medical University
Guangzhou Bioresette Biomedical Technology Co., Ltd.

Recruiting

EBV CAR-T Cells for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Roswell Park Cancer Institute

Completed

Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

Lymphoma | Unspecified Childhood Solid Tumor, Protocol Specific | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Unspecified Adult Solid Tumor, Protocol Specific | Myelodysplastic/Myeloproliferative Diseases | Nonmalignant Neoplasm

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Recruiting

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors

Solid Tumor | Liposarcoma | Rhabdomyosarcoma | Wilms Tumor | Malignant Rhabdoid Tumor | Yolk Sac Tumor | Liver Cell Carcinoma | Embryonal Sarcoma of the Liver

United States
M.D. Anderson Cancer Center

Completed

FM 140 vs FM100 Study in Patients With Multiple Myeloma

Multiple Myeloma

United States
University of Washington
Incyte Corporation

Recruiting

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

United States
Targazyme, Inc.

Unknown

Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation

Lymphoma | Leukemia | Hodgkin's Lymphoma | Transplantation Infection | Myelodysplastic Syndrome (MDS) | Non-Hodgkin's Lymphoma (NHL) | Blood And Marrow Transplantation

United States
Hoffmann-La Roche

Active, not recruiting

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation (CRISTALLO)

Chronic Lymphocytic Leukemia (CLL)

United States, Italy, Australia, Spain, France
Memorial Sloan Kettering Cancer Center
Boston Children's Hospital; Fred Hutchinson Cancer Center; Children's Hospital... and other collaborators

Completed

Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine

Leukemia | Myelodysplastic Syndrome | Aplastic Anemia

United States
Hoffmann-La Roche

Terminated

A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.

Diffuse Large B-Cell Lymphoma

Romania
Arbeitsgemeinschaft medikamentoese Tumortherapie
Roche Pharma AG; Celgene Corporation

Completed

Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL

Leukemia, Lymphocytic, Chronic, B-Cell

Austria
M.D. Anderson Cancer Center

Active, not recruiting

A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)

Colon Cancer | Resected Stage

United States
Fujian Cancer Hospital

Not yet recruiting

TIL Cells for the Treatment of the Advanced Solid Tumors Patients

Solid Tumor
Asan Medical Center

Unknown

HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors

Acute Leukemia | Myelodysplastic Syndrome | Solid Tumors

Korea, Republic of
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Chronic Lymphocytic Leukemia

Leukemia

United States
National Cancer Institute (NCI)

Recruiting

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Lymphoplasmacytic Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Grade 3b Follicular... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Ann Arbor Stage III Non-Hodgkin Lymphoma | Ann Arbor Stage IV Non-Hodgkin Lymphoma | Ann Arbor Stage II Non-Hodgkin Lymphoma

United States
Huiqiang Huang

Recruiting

Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma

Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Transformed Lymphoma | EBV-Positive DLBCL, Nos | ALK-Positive Anaplastic Large Cell Lymphoma | Follicular Lymphoma Grade IIIb

China
Porteus, Matthew, MD

Recruiting

Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab

Fanconi Anemia

United States
Artiva Biotherapeutics, Inc.

Recruiting

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Non Hodgkin Lymphoma

United States

Search clinical trials for: rituximab,fludarabine, cyclophosphamide

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations